Pfizer: An Oversold Pharma Stock in Recovery

Some say the art of investing is the ability of catching falling knives. Pfizer Inc. (PFE, Financial) shares have sold off in 2023 and represent an attractive opportunity after having likely bottomed out.Attractive opportunity despite poor stock performance The pharmaceutical company's dividend yield of approximately 5.80% naturally draws the attention of the market and seasoned investors alike. Approximately $9 billion is spent by the company in dividend payments per year, despite a free cash flow of only ...